O	0	10	Evaluation
O	11	13	of
O	14	17	the
O	18	24	effect
O	25	27	of
B-intervention	28	29	N
I-intervention	29	30	-
I-intervention	30	44	acetylcysteine
O	45	47	on
O	48	51	the
O	52	62	prevention
O	63	66	and
O	67	79	amelioration
O	80	82	of
B-condition	83	93	paclitaxel
I-condition	93	94	-
I-condition	94	101	induced
I-condition	102	112	peripheral
I-condition	113	123	neuropathy
O	124	126	in
O	127	133	breast
O	134	140	cancer
O	141	149	patients
O	149	150	:
O	151	152	a
O	153	163	randomized
O	164	174	controlled
O	175	180	study
O	180	181	.

O	182	185	The
O	186	189	aim
O	190	192	of
O	193	196	the
O	197	204	current
O	205	210	study
O	211	214	was
O	215	217	to
O	218	226	evaluate
O	227	230	the
O	231	237	effect
O	238	240	of
O	241	242	N
O	242	243	-
O	243	257	acetylcysteine
O	258	259	(
O	259	262	NAC
O	262	263	)
O	264	266	on
O	267	270	the
O	271	280	incidence
O	281	284	and
O	285	293	severity
O	294	296	of
O	297	307	paclitaxel
O	307	308	-
O	308	315	induced
O	316	326	peripheral
O	327	337	neuropathy
O	338	339	(
O	339	343	PIPN
O	343	344	)
O	345	347	in
O	348	354	breast
O	355	361	cancer
O	362	370	patients
O	370	371	.

O	372	373	A
O	374	385	prospective
O	386	396	randomized
O	397	407	controlled
O	408	412	open
O	413	418	label
O	419	424	study
O	425	428	was
O	429	438	conducted
O	439	441	on
B-total-participants	442	444	75
B-eligibility	445	451	breast
I-eligibility	452	458	cancer
I-eligibility	459	467	patients
I-eligibility	468	477	receiving
I-eligibility	478	486	adjuvant
I-eligibility	487	497	paclitaxel
I-eligibility	498	500	80
I-eligibility	501	503	mg
I-eligibility	503	504	/
I-eligibility	504	506	m2
I-eligibility	507	513	weekly
I-eligibility	514	517	for
I-eligibility	518	520	12
I-eligibility	521	526	weeks
O	526	527	.

O	528	536	Eligible
O	537	545	patients
O	546	550	were
O	551	561	randomized
O	562	564	to
O	565	571	either
O	572	575	the
O	576	579	low
O	580	584	dose
O	585	590	group
O	590	591	;
O	592	596	1200
O	597	599	mg
O	600	605	daily
O	606	609	NAC
O	609	610	,
O	611	614	the
O	615	619	high
O	620	624	dose
O	625	630	group
O	630	631	;
O	632	636	1200
O	637	639	mg
O	640	643	NAC
O	644	649	twice
O	650	655	daily
O	656	658	or
O	659	662	the
B-control	663	670	control
I-control	671	676	group
O	676	677	;
O	678	686	received
O	687	697	paclitaxel
O	698	702	only
O	702	703	.

O	704	707	The
O	708	715	primary
O	716	724	endpoint
O	725	728	was
O	729	732	the
B-outcome-Measure	733	742	incidence
I-outcome-Measure	743	745	of
I-outcome-Measure	746	755	different
I-outcome-Measure	756	762	grades
I-outcome-Measure	763	765	of
I-outcome-Measure	766	770	PIPN
O	771	776	using
O	777	785	National
O	786	792	Cancer
O	793	802	Institute
O	802	803	'
O	803	804	s
O	805	811	common
O	812	820	toxicity
O	821	829	criteria
O	830	833	for
O	834	841	adverse
O	842	847	event
O	848	849	(
O	849	852	NCI
O	852	853	-
O	853	858	CTCAE
O	858	859	)
O	860	865	while
O	866	875	secondary
O	876	885	endpoints
O	886	890	were
O	891	894	the
B-outcome-Measure	895	903	severity
I-outcome-Measure	904	906	of
I-outcome-Measure	907	911	PIPN
O	912	917	using
O	918	926	modified
O	927	932	total
O	933	943	neuropathy
O	944	949	score
O	950	951	(
O	951	955	mTNS
O	955	956	)
O	956	957	,
B-outcome-Measure	958	965	quality
I-outcome-Measure	966	968	of
I-outcome-Measure	969	973	life
I-outcome-Measure	974	975	(
I-outcome-Measure	975	978	QOL
I-outcome-Measure	978	979	)
O	980	985	using
O	986	996	Functional
O	997	1007	Assessment
O	1008	1010	of
O	1011	1017	Cancer
O	1018	1025	Therapy
O	1025	1026	/
O	1026	1037	Gynecologic
O	1038	1046	Oncology
O	1047	1052	Group
O	1052	1053	-
O	1053	1066	Neurotoxicity
O	1067	1068	(
O	1068	1072	FACT
O	1072	1073	-
O	1073	1076	GOG
O	1076	1077	-
O	1077	1080	NTX
O	1080	1081	)
O	1082	1090	subscale
O	1090	1091	,
B-outcome-Measure	1092	1097	serum
I-outcome-Measure	1098	1103	nerve
I-outcome-Measure	1104	1110	growth
I-outcome-Measure	1111	1117	factor
I-outcome-Measure	1118	1119	(
I-outcome-Measure	1119	1122	NGF
I-outcome-Measure	1122	1123	)
O	1123	1124	,
O	1125	1128	and
B-outcome-Measure	1129	1134	serum
I-outcome-Measure	1135	1150	malondialdehyde
I-outcome-Measure	1151	1152	(
I-outcome-Measure	1152	1155	MDA
I-outcome-Measure	1155	1156	)
O	1156	1157	.

O	1158	1160	At
O	1161	1164	the
O	1165	1168	end
O	1169	1171	of
O	1172	1175	the
O	1176	1178	12
O	1178	1179	-
O	1179	1183	week
O	1184	1190	period
O	1190	1191	,
O	1192	1195	the
B-outcome	1196	1205	incidence
I-outcome	1206	1208	of
I-outcome	1209	1214	grade
I-outcome	1215	1216	(
I-outcome	1216	1217	2
I-outcome	1217	1218	,
I-outcome	1219	1220	3
I-outcome	1220	1221	)
I-outcome	1222	1232	peripheral
I-outcome	1233	1243	neuropathy
O	1244	1247	was
O	1248	1261	significantly
O	1262	1267	lower
O	1268	1270	in
O	1271	1274	the
O	1275	1279	high
O	1280	1284	dose
O	1285	1290	group
O	1291	1292	(
B-iv-bin-percent	1292	1294	28
I-iv-bin-percent	1294	1295	.
I-iv-bin-percent	1295	1296	6
I-iv-bin-percent	1296	1297	%
O	1297	1298	)
O	1299	1307	compared
O	1308	1310	to
O	1311	1314	the
O	1315	1318	low
O	1319	1323	dose
O	1324	1329	group
O	1330	1331	(
B-iv-bin-percent	1331	1333	61
I-iv-bin-percent	1333	1334	.
I-iv-bin-percent	1334	1335	9
I-iv-bin-percent	1335	1336	%
O	1336	1337	)
O	1338	1341	and
O	1342	1345	the
O	1346	1353	control
O	1354	1359	group
O	1360	1361	(
B-cv-bin-percent	1361	1364	100
I-cv-bin-percent	1364	1365	%
O	1365	1366	)
O	1366	1367	,
O	1368	1369	p
O	1370	1375	value
O	1376	1377	<
O	1378	1379	0
O	1379	1380	.
O	1380	1383	001
O	1383	1384	.

O	1385	1386	A
O	1387	1398	significant
O	1399	1410	improvement
O	1411	1413	in
O	1414	1417	the
B-outcome	1418	1422	mTNS
I-outcome	1423	1426	and
I-outcome	1427	1430	QOL
I-outcome	1431	1437	scores
O	1438	1441	was
O	1442	1450	observed
O	1451	1456	after
O	1457	1458	6
O	1459	1462	and
O	1463	1465	12
O	1466	1471	weeks
O	1472	1474	in
O	1475	1478	the
O	1479	1483	high
O	1484	1488	dose
O	1489	1494	group
O	1495	1498	and
O	1499	1502	the
O	1503	1506	low
O	1507	1511	dose
O	1512	1517	group
O	1518	1526	compared
O	1527	1529	to
O	1530	1533	the
O	1534	1541	control
O	1541	1542	,
O	1543	1544	p
O	1545	1550	value
O	1551	1552	<
O	1553	1554	0
O	1554	1555	.
O	1555	1558	001
O	1558	1559	.

O	1560	1573	Significantly
O	1574	1580	higher
B-outcome	1581	1587	levels
I-outcome	1588	1590	of
I-outcome	1591	1596	serum
I-outcome	1597	1600	NGF
O	1601	1603	in
O	1604	1607	the
O	1608	1612	high
O	1613	1617	dose
O	1618	1623	group
O	1624	1627	and
O	1628	1633	lower
B-outcome	1634	1639	level
I-outcome	1640	1642	of
I-outcome	1643	1648	serum
I-outcome	1649	1652	MDA
O	1653	1655	in
O	1656	1659	the
O	1660	1664	high
O	1665	1669	dose
O	1670	1673	and
O	1674	1677	the
O	1678	1681	low
O	1682	1686	dose
O	1687	1692	group
O	1693	1697	were
O	1698	1706	observed
O	1706	1707	.

O	1708	1712	Oral
O	1713	1716	NAC
O	1717	1718	(
O	1718	1722	1200
O	1723	1725	mg
O	1726	1730	once
O	1731	1734	and
O	1735	1740	twice
O	1741	1746	daily
O	1746	1747	)
O	1748	1753	might
O	1754	1760	reduce
O	1761	1764	the
O	1765	1774	incidence
O	1775	1778	and
O	1779	1787	severity
O	1788	1790	of
O	1791	1795	PIPN
O	1796	1799	and
O	1800	1807	improve
O	1808	1811	the
O	1812	1820	patients
O	1820	1821	'
O	1822	1825	QOL
O	1825	1826	.

O	1827	1835	Clinical
O	1836	1841	Trial
O	1841	1842	.
O	1842	1845	gov
O	1846	1858	registration
O	1859	1865	number
O	1865	1866	:
O	1867	1878	NCT03492047
O	1878	1879	.
